Samuel D. Saibil

Samuel D. Saibil

Auto-generated profile, based on publicly available information

Samuel D. Saibil

Princess Margaret Cancer Centre, University Health Network, Toronto, Canada

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Cancer Research
Verified
Journal Article
Open access
PDF file
SSSamuel D. Saibil
Samuel D. Saibil
MPMichael St. Paul
Michael St. Paul
RLRobert C. Laister
Robert C. Laister
CGCarlos R. Garcia-Batres
Carlos R. Garcia-Batres
KIKavita Israni-Winger
Kavita Israni-Winger
POPamela S. Ohashi
Pamela S. Ohashi
Memory CD8+ T cells (Tmem) are superior mediators of adoptive cell therapy (ACT) compared with effector CD8+ T cells (Teff) due to increased persistence in vivo. Underpinning Tmem survival is a shift in cellular metabolism away from aerobic glycolysis towards fatty acid oxidation (FAO). Here we investigated the impact of the peroxisome proliferator-activated receptor (PPAR) agonist GW501516 (GW), an agent known to boost FAO in other tissues, on CD8+ T-cell metabolism, function, and efficacy in a murine ACT model. Via activation of both PPARα and PPARδ/β, GW treatment increased expression of carnitine palmitoyl transferase 1a, the rate-limiting enzyme of FAO, in activated CD8+ T cells. Using a metabolomics approach, we demonstrated that GW increased the abundance of multiple different acylcarnitines, consistent with enhanced FAO. T cells activated in the presence of GW and inflammatory signals, either mature dendritic cells or IL12, also demonstrated enhanced production of IFNγ and expression of T-bet. Despite high expression of T-bet, a characteristic of short-lived effector cells, GW-treated cells demonstrated enhanced persistence in vivo and superior efficacy in a model of ACT. Collectively, these data identify combined PPARα and PPARδ/β agonists as attractive candidates for further studies and rapid translation into clinical trials of ACT. Significance: Dual activation of peroxisome proliferator-activated receptors α and δ improves the efficacy of adoptive cell therapy by reprogramming T-cell metabolism and cytokine expression.

1 March 2020 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
MPMichael St. Paul
Michael St. Paul
SSSamuel D. Saibil
Samuel D. Saibil
SLScott C. Lien
Scott C. Lien
SHSeongJun Han
SeongJun Han
ASAzin Sayad
Azin Sayad
POPamela S. Ohashi
Pamela S. Ohashi
CD8+ T cells can be polarized into several different subsets as defined by the cytokines they produce and the transcription factors that govern their differentiation. Here, we identified the polarizing conditions to induce an IL22-producing CD8+ Tc22 subset, which is dependent on IL6 and the aryl hydrocarbon receptor transcription factor. Further characterization showed that this subset was highly cytolytic and expressed a distinct cytokine profile and transcriptome relative to other subsets. In addition, polarized Tc22 were able to control tumor growth as well as, if not better than, the traditional IFNγ-producing Tc1 subset. Tc22s were also found to infiltrate the tumors of human patients with ovarian cancer, comprising up to approximately 30% of expanded CD8+ tumor-infiltrating lymphocytes (TIL). Importantly, IL22 production in these CD8+ TILs correlated with improved recurrence-free survival. Given the antitumor properties of Tc22 cells, it may be prudent to polarize T cells to the Tc22 lineage when using chimeric antigen receptor (CAR)-T or T-cell receptor (TCR) transduction–based immunotherapies.

15 December 2017 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
CTCharles W. Tran
Charles W. Tran
SSSamuel D. Saibil
Samuel D. Saibil
TBThierry Le Bihan
Thierry Le Bihan
SHSara R. Hamilton
Sara R. Hamilton
KLKarl S. Lang
Karl S. Lang
POPamela S. Ohashi
Pamela S. Ohashi
The decision between T cell activation and tolerance is governed by the spatial and temporal integration of diverse molecular signals and events occurring downstream of TCR and costimulatory or coinhibitory receptor engagement. The PI3K–protein kinase B (PKB; also known as Akt) signaling pathway is a central axis in mediating proximal signaling events of TCR and CD28 engagement in T cells. Perturbation of the PI3K–PKB pathway, or the loss of negative regulators of T cell activation, such as the E3 ubiquitin ligase Cbl-b, have been reported to lead to increased susceptibility to autoimmunity. In this study, we further examined the molecular pathway linking PKB and Cbl-b in murine models. Our data show that the protein kinase GSK-3, one of the first targets identified for PKB, catalyzes two previously unreported phosphorylation events at Ser476 and Ser480 of Cbl-b. GSK-3 inactivation by PKB abrogates phosphorylation of Cbl-b at these two sites and results in reduced Cbl-b protein levels. We further show that constitutive activation of PKB in vivo results in a loss of tolerance that is mediated through the downregulation of Cbl-b. Altogether, these data indicate that the PI3K–PKB–GSK-3 pathway is a novel regulatory axis that is important for controlling the decision between T cell activation and tolerance via Cbl-b.

11 November 2025 in Cancer Research
Verified
Journal Article
Closed access
VRVincent Rondeau
Vincent Rondeau
SBSuraj Bansal
Suraj Bansal
MBMarco M. Buttigieg
Marco M. Buttigieg
AZAndy G.X. Zeng
Andy G.X. Zeng
DCDarryl Y. Chan
Darryl Y. Chan
RVRobert J. Vanner
Robert J. Vanner
Somatic mutations inactivating Tet methylcytosine dioxygenase 2 (TET2) are among the most common drivers of clonal hematopoiesis (CH). TET2 inactivation is associated with monocyte-derived inflammation and improved chimeric antigen receptor T-cell function, suggesting that it might also affect immunotherapy response. In this study, we found that hematopoietic Tet2 mutation in mouse models enhanced the immune checkpoint blockade (ICB) response, which required the combined presence of phagocytes, CD4+, and CD8+ T cells. The effect was lost with myeloid- or T-cell–restricted Tet2 inactivation or in mice with 20% Tet2-mutant hematopoiesis. Mechanistically, in Tet2-mutant tumor-infiltrating leukocytes, ICB preferentially restricted cell states linked to tumor progression while inducing antitumor states. Tet2-mutant monocytes activated costimulatory programs, whereas Tet2-mutant T cells showed enhanced T-cell memory signatures, alongside decreased exhaustion and regulatory phenotypes. Clinically, tumors from patients with colorectal cancer and melanoma with TET2-mutant CH showed enhanced immune infiltration, inflammation, and T-cell activation. In patients with melanoma treated with ICB, TET2-mutant CH was associated with six-fold greater odds of clinical benefit. Collectively, this work demonstrates that hematopoietic TET2 inactivation primes leukocytes for antitumor states associated with immunotherapy response and provides a potential biomarker for personalized therapy. Significance: TET2 mutations promote antitumor leukocyte states that can potentiate the efficacy of immunotherapy with checkpoint blockade. See related commentary by Yuan and Guryanova, p. 825

13 August 2025 in Pigment Cell & Melanoma Research
Verified
Journal Article
Open access
MNMariana Macambira Noronha
Mariana Macambira Noronha
LSLuís Felipe Leite da Silva
Luís Felipe Leite da Silva
LALuiz Felipe Costa de Almeida
Luiz Felipe Costa de Almeida
PPPedro Passos
Pedro Passos
PRPedro Cotta Abrahão Reis
Pedro Cotta Abrahão Reis
ESErick F. Saldanha
Erick F. Saldanha
Metastatic uveal melanoma (mUM) is a rare disease associated with poor prognosis and limited therapeutic options. Recent studies showed that detecting ctDNA is feasible and can aid treatment decisions for patients with mUM. We systematically searched PubMed, EMBASE, and Cochrane databases for eligible studies published up to May 2025 that included patients with mUM and reported data on the association between ctDNA and survival outcomes (OS and PFS). Statistical analyses were performed using Review Manager 5.4 software. Of the initial 450 records, seven studies met eligibility, including 518 patients with mUM. At baseline, ctDNA positivity was associated with significantly worse PFS (HR 2.34; 95% CI 1.56–3.51; p < 0.01; I2 = 0%) and OS (HR 3.32; 95% CI 2.09–5.29; p < 0.01; I2 = 48%). In patients treated with tebentafusp, ctDNA clearance was associated with superior OS (HR 0.19; 95% CI 0.07–0.49; p < 0.01; I2 = 46%) and any decrease in ctDNA was associated with better OS (HR 0.42; 95% CI 0.22–0.80; p < 0.01; I2 = 0%). This meta‐analysis underscores ctDNA as a potential predictor of worse survival in patients with mUM, highlighting its potential to refine risk stratification and guide treatment strategies.Trial Registration: International Prospective Register of Systematic Reviews (PROSPERO): CRD42025638076

4 April 2023
Verified
Other
Open access
MPMichael St. Paul
Michael St. Paul
SSSamuel D. Saibil
Samuel D. Saibil
SLScott C. Lien
Scott C. Lien
SHSeongJun Han
SeongJun Han
ASAzin Sayad
Azin Sayad
POPamela S. Ohashi
Pamela S. Ohashi
CD8+ T cells can be polarized into several different subsets as defined by the cytokines they produce and the transcription factors that govern their differentiation. Here, we identified the polarizing conditions to induce an IL22-producing CD8+ Tc22 subset, which is dependent on IL6 and the aryl hydrocarbon receptor transcription factor. Further characterization showed that this subset was highly cytolytic and expressed a distinct cytokine profile and transcriptome relative to other subsets. In addition, polarized Tc22 were able to control tumor growth as well as, if not better than, the traditional IFNγ-producing Tc1 subset. Tc22s were also found to infiltrate the tumors of human patients with ovarian cancer, comprising up to approximately 30% of expanded CD8+ tumor-infiltrating lymphocytes (TIL). Importantly, IL22 production in these CD8+ TILs correlated with improved recurrence-free survival. Given the antitumor properties of Tc22 cells, it may be prudent to polarize T cells to the Tc22 lineage when using chimeric antigen receptor (CAR)-T or T-cell receptor (TCR) transduction–based immunotherapies.